Please enable Javascript
RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
EVOLUTION: Lu-PSMA With Ipi/Nivo in mCRPC
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
View More
TheraP: Clonal Hematopoiesis in mCRPC Patients Receiving Lu-PSMA or Cabazitaxel
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
View More
ProstACT GLOBAL: TLX591 and Best SOC for Patients With PSMA-Expressing mCRPC
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
View More
VIOLET: Terbium-161 Radioligand Treatment in Patients With mCRPC
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
View More
Cabazitaxel vs Lutetium-177: Efficacy for Metastatic Castration-Resistant Prostate Cancer
Zeynep Irem Ozay, MD
RLT
|
June 4, 2025
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
View More
BULLSEYE: Lu-PSMA in Oligometastatic HSPC
Bastiaan Privé, MD
RLT
|
June 2, 2025
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
View More
ENZA-p: Predictive, Prognostic Value of Baseline PSMA Total Tumor Volume, SUV Mean
Louise Emmett, MD
RLT
|
May 31, 2025
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
View More
Higher Progression-Free Survival Provided by LuPSMA Plus Ipi/Nivo Over LuPSMA Alone in Patients With mCRPC
Emily Menendez
RLT
|
May 29, 2025
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Read More
18F-Flotufolastat-PET Aids in Detection of Hematologic Malignancy in Patients With mCRPC Treated With 177Lu
Emily Menendez
RLT
|
May 23, 2025
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
Read More
The Role of PSMA-Targeted Antibodies in Prostate Cancer
Scott Tagawa, MD, MS, FACP
Prostate Cancer
|
April 4, 2025
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
View More
PSMA RLT for Oligometastatic Prostate Cancer
Amar Kishan, MD
RLT
|
April 3, 2025
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
View More
FDA Approves 177Lu Vipivotide Tetraxetan for PSMA+ mCRPC Treatment Before Chemotherapy
Emily Menendez
CRPC
|
March 31, 2025
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Read More
Evaluating Safety and Efficacy of PSMA Therapy in the Castration-Sensitive Setting
Michael Morris, MD
mHSPC
|
March 31, 2025
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
View More
Improving Prostate Cancer Outcomes With Combination Therapy
Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD
RLT
|
March 31, 2025
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
View More
PSMA and Beyond 2025: Reviewing the Agenda
Jérémie Calais, MD, PhD
RLT
|
March 26, 2025
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
View More
ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC
Emily Menendez
RLT
|
March 7, 2025
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Read More
Comparing OS and PFS Rates of Patients With mCRPC and BRCA, PTEN/TP53/RB1 Mutations
Emily Menendez
RLT
|
January 7, 2025
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Read More
PSMAfore: Radioligand Therapy in the Future of Prostate Cancer Treatment
Oliver Sartor, MD
RLT
|
November 21, 2024
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
View More
The Landscape of Radiopharmaceuticals and PARP Inhibitors in CRPC
Irbaz B. Riaz, MBBS, PhD
CRPC
|
November 5, 2024
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
View More
Uromigos Live 2024 Radioligands Part 5: Novel Radioligands in CRPC
Brian Rini, MD, FASCO
RLT
|
October 29, 2024
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
View More
Load More
Advertisement
Advertisement